Intravenous Doxycycline, Azithromycin, or Both for Severe Scrub Typhus

Area of Science:

• Infectious Diseases
• Tropical Medicine
• Clinical Pharmacology

Background:

• Severe scrub typhus is a reemerging zoonotic infection with unclear optimal antibiotic treatment.
• This condition can lead to severe organ involvement, including respiratory, hepatic, cardiovascular, renal, and neurologic complications.

Purpose of the Study:

• To compare the efficacy of intravenous doxycycline, azithromycin, and combination therapy in treating severe scrub typhus.
• To determine the best antibiotic regimen for reducing mortality and complications in patients with severe scrub typhus.

Main Methods:

• A multicenter, double-blind, randomized controlled trial involving 794 patients aged 15 years or older with severe scrub typhus.
• Patients received a 7-day course of intravenous doxycycline, azithromycin, or a combination of both.
• The primary outcome was a composite of all-cause death at day 28, persistent complications at day 7, and persistent fever at day 5.

Main Results:

• Combination therapy significantly reduced the primary composite outcome compared to doxycycline alone (33% vs. 47%) and azithromycin alone (33% vs. 48%).
• No significant difference in outcomes was observed between doxycycline and azithromycin monotherapy groups.
• Adverse events and 28-day mortality rates were similar across all three treatment groups.

Conclusions:

• Combination therapy with intravenous doxycycline and azithromycin is a superior treatment option for severe scrub typhus compared to monotherapy.
• This combination therapy offers an improved therapeutic strategy for managing severe cases of this neglected zoonotic disease.